T2 Biosystems (NASDAQ:TTOO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note released on Tuesday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Stock Up 7.3 %

TTOO stock opened at $0.25 on Tuesday. The business has a 50 day moving average of $0.41 and a 200 day moving average of $2.00. T2 Biosystems has a twelve month low of $0.22 and a twelve month high of $6.95.

Institutional Trading of T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC bought a new position in T2 Biosystems, Inc. (NASDAQ:TTOO) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 23.18% of the company’s stock.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.